Approximately 20 to 25% of breast cancers [1,2] and 30% of gastric cancers [3] have overexpression and/or gene amplification of human epidermal growth factor receptor 2 (HER2), which serves as both a poor prognostic marker and a therapeutic target. This evidence concerns the gene ERBB2 and gastric cancer.